Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.385 USD | -3.00% | -1.28% | -12.48% |
16/05 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 | |
29/04 | AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.48% | 2.02Cr | |
+12.30% | 12TCr | |
+12.15% | 11TCr | |
-8.14% | 2.39TCr | |
-1.69% | 2.16TCr | |
-10.60% | 1.9TCr | |
-41.25% | 1.7TCr | |
-15.33% | 1.63TCr | |
+5.80% | 1.41TCr | |
+28.03% | 1.2TCr |
- Stock Market
- Equities
- AIM Stock
- News AIM ImmunoTech Inc.
- AIM ImmunoTech : Signs Clinical Trial Agreement to Test Ampligen Against Common Cold, Influenza A Viruses